



# High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+ /HER2- Disease

## Incidence of HR+ /HER2- breast cancer

Most patients with early breast cancer (EBC) have hormone receptor-positive (HR+)/HER2-negative (HER2-) disease<sup>1</sup>


### Breast Cancer Molecular Subtypes at Diagnosis<sup>1</sup>



**About 70%** of EBC is HR+ /HER2-  
 EBC has no spread detected beyond the breasts and lymph nodes in and around the breasts and has gone only as far as the lymph nodes in the armpit(s).<sup>2</sup> Some patients with EBC have cancer cells that are **more aggressive and more likely to grow and spread quickly**, which means there is a **higher risk of the cancer recurring**<sup>3,4</sup>

## Some clinical features of high-risk disease

Patients with HR+ /HER2- breast cancer at high-risk of recurrence may present with<sup>5</sup>




**≥4 positive axillary lymph nodes (ALNs)**

or 1-3 positive ALNs with



**Grade 3 disease**

or



**Tumor size ≥5 cm**

**3.9x**

Compared with grade 1 disease, patients with grade 3 tumors have a **3.9x increased risk of distant recurrence** over 10 years<sup>6</sup>


**2.0x**

Similarly, patients with stage III disease are at a **2.0x increased risk of recurrence** over 10 years compared to patients with stage I disease<sup>7</sup>

As health care providers, it is important to recognize these features associated with a higher risk of recurrence

## Recurrence rates

**~30%** of patients with high-risk, HR+ /HER2- EBC may experience recurrence, often with distant metastases<sup>5</sup>




**About 3 in 10 patients with high-risk, HR+ /HER2- EBC will experience disease recurrence within 5 years<sup>5</sup>**

## Sites of recurrence<sup>8,9</sup>

Most disease recurrence occurs at distant sites. Common sites of distant recurrence include the bone, liver, lungs, and brain. Although local and regional recurrences are treated with curative intent, **distant recurrences remain largely incurable but are treatable**

**Location and incidence of recurrence** ▶  
 Distant recurrence: 60%-70% | Locoregional recurrence: 20%-40%




1. Howlader N, et al. *J Natl Cancer Inst.* 2014;106(5):dju055.  
 2. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer>. (Accessed March 3, 2023).  
 3. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/recurrent-cancer>. (Accessed March 3, 2023).  
 4. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aggressive>. (Accessed March 3, 2023).  
 5. Sheffield KM, et al. *Future Oncol.* 2022;18(21):2667-2682.  
 6. Holleccek B, et al. *BMC Cancer.* 2019;19(1):520.  
 7. Cheng L, et al. *Cancer Epidemiology Biomarkers & Prevention.* 2012;21(5):800-809.  
 8. Gerber B, et al. *Dtsch Arztebl Int.* 2010;107(6):85-89.  
 9. Cardoso F, et al. *Ann Oncol.* 2020;31(12):1623-1649.



# High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+ /HER2- Disease

## EBC: Clinical and pathological factors associated with a higher risk of recurrence



1. Cheng L, et al. *Cancer Epidemiol Biomarkers Prev.* 2012;21(5):800-809.  
 2. Holleccek B, et al. *BMC Cancer.* 2019;19(1):520.  
 3. Pan H, et al. *N Engl J Med.* 2017;377(19):1836-1846.